Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for InSilico Medicine Cayman TopCo's Debt-to-Equity or its related term are showing as below:
ISLMF'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.01 Med: 0 Max: 0.01
Current: 0.01
During the past 4 years, the highest Debt-to-Equity Ratio of InSilico Medicine Cayman TopCo was 0.01. The lowest was -0.01. And the median was 0.00.
ISLMF's Debt-to-Equity is ranked better than 99.96% of 2249
companies
in the Software industry
Industry Median: 0.2
vs ISLMF: 0.01
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
InSilico Medicine Cayman TopCo Debt-to-Equity Related Terms
InSilico Medicine Cayman TopCo Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InSilico Medicine Cayman TopCo Debt-to-Equity Chart
For the Software - Infrastructure subindustry, InSilico Medicine Cayman TopCo's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InSilico Medicine Cayman TopCo Debt-to-Equity vs Software Industry
For the Software industry and Technology sector, InSilico Medicine Cayman TopCo's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where InSilico Medicine Cayman TopCo's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InSilico Medicine Cayman TopCo (ISLMF) has a Debt-to-Equity of 0.01 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on InSilico Medicine Cayman TopCo and its competitors. According to the industry distribution chart, InSilico Medicine Cayman TopCo ranks #1 out of 2249 companies in the Software industry, placing it in the top 0%.
Is InSilico Medicine Cayman TopCo's Debt-to-Equity too high?
InSilico Medicine Cayman TopCo's current Debt-to-Equity is 0.01. The Software industry median Debt-to-Equity is 0.20. InSilico Medicine Cayman TopCo's value of 0.01 is 95% below this industry median. Based on the distribution chart, InSilico Medicine Cayman TopCo ranks #1 out of 2249 companies in the Software industry, which is in the top quartile — a strong position relative to peers. Overall, InSilico Medicine Cayman TopCo has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does InSilico Medicine Cayman TopCo's Debt-to-Equity compare to ?
According to the Software industry distribution chart, InSilico Medicine Cayman TopCo ranks #1 out of 2249 companies for Debt-to-Equity. This places InSilico Medicine Cayman TopCo in the top 0% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.20. InSilico Medicine Cayman TopCo's value of 0.01 is 95% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Software company?
The median Debt-to-Equity among Software companies is 0.20, based on 2,249 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. InSilico Medicine Cayman TopCo's current Debt-to-Equity of 0.01 is 95% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on InSilico Medicine Cayman TopCo and its competitors. For the Software industry, the median Debt-to-Equity is 0.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InSilico Medicine Cayman TopCo's current Debt-to-Equity is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InSilico Medicine Cayman TopCo stock overvalued right now?
InSilico Medicine Cayman TopCo (ISLMF) has a current Debt-to-Equity of 0.01. The current Debt-to-Equity is 0.01 and 95% below the Software industry median of 0.20. InSilico Medicine Cayman TopCo's overall GF Score™ is 13/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For InSilico Medicine Cayman TopCo (ISLMF), the current Debt-to-Equity is 0.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
InSilico Medicine Cayman TopCo is engaged in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. It has generated multiple clinical-stage or IND-enabling assets using Pharma.AI, an AI-enabled platform that supports drug discovery and development activities. The company operates under a project-based business model, deriving revenue from out-licensing and collaboration arrangements. Geographically, the company generates revenue from multiple countries, with the majority of the revenue coming from United States.
13GF Score
Get the complete analysis for ISLMF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISLMF has been successfully added to your 
